ANON
MCID: ANR007
MIFTS: 61

Anorexia Nervosa (ANON)

Categories: Mental diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Anorexia Nervosa

MalaCards integrated aliases for Anorexia Nervosa:

Name: Anorexia Nervosa 57 11 75 73 53 43 14 16 71 31 33
Anorexia Nervosa, Susceptibility to 57 12 38
Anorexia Nervosa, Susceptibility to, 1 57 28
Anon 57 73
an - [anorexia Nervosa] 33
Anorexia Nervosa 1 57
an 57

Classifications:



Summaries for Anorexia Nervosa

OMIM®: 57 Eating disorders are characterized by severe disturbances in eating behavior that typically have onset during late adolescence and early adulthood. Three major types are recognized: anorexia nervosa (AN), bulimia nervosa (BN; 607499), and eating disorder not otherwise specified (EDNOS). AN is characterized by obsessive fear of weight gain, severely restricted eating, and low body weight. In women, AN has the highest mortality among the psychiatric disorders (Sullivan, 1995). AN is divided into 2 clinical subtypes, restricting anorexia nervosa (RAN) and binge-eating/purging anorexia nervosa (BPAN). BN can occur at any body weight and is characterized by binge-eating and compensatory weight-loss behaviors. Family studies have indicated an increased prevalence of eating disorders in relatives of probands with AN (Lilenfeld et al., 1998), and twin studies (Holland et al., 1984; Wade et al., 2000) have estimated concordance rates for monozygotic twins with AN to be 52 to 56%, whereas concordance rates for dizygotic twins with AN have been estimated to be 5 to 11% (Grice et al., 2002). (606788) (Updated 08-Dec-2022)

MalaCards based summary: Anorexia Nervosa, also known as anorexia nervosa, susceptibility to, is related to eating disorder and body dysmorphic disorder, and has symptoms including decrease in appetite An important gene associated with Anorexia Nervosa is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Olanzapine and Fluoxetine have been mentioned in the context of this disorder. Affiliated tissues include bone, prefrontal cortex and brain, and related phenotypes are Reduced mammosphere formation and nervous system

UniProtKB/Swiss-Prot: 73 An eating disorder characterized by the lack or loss of appetite, excess fear of becoming overweight, body image disturbance, significant weight loss, refusal to maintain minimal normal weight, and amenorrhea.

Disease Ontology: 11 An eating disorder characterized by refusal to maintain a healthy body weight, and an obsessive fear of gaining weight due to a distorted self image.

Wikipedia: 75 Anorexia nervosa, often referred to simply as anorexia, is an eating disorder characterized by low... more...

Related Diseases for Anorexia Nervosa

Diseases related to Anorexia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 875)
# Related Disease Score Top Affiliating Genes
1 eating disorder 32.6 SLC6A4 RETN PYY POMC NPY LEPR
2 body dysmorphic disorder 32.6 SLC6A4 IGF1 HTR2A
3 bulimia nervosa 32.5 SLC6A4 PYY NPY LEP HTR2A GHRL
4 amenorrhea 32.0 PYY PRL POMC NPY LEP IGF1
5 personality disorder 31.9 SLC6A4 PRL HTR2A CRH CCK BDNF
6 alexithymia 31.8 SLC6A4 HTR2A CRH BDNF
7 autism spectrum disorder 31.8 SLC6A4 LEP IGF1 GHRL BDNF ADIPOQ
8 nutritional deficiency disease 31.8 RETN PYY NPY LEPR LEP IGF1
9 autism 31.7 SLC6A4 LEP IGF1 HTR2A GHRL BDNF
10 insulin-like growth factor i 31.6 PRL LEP IGF1 GHRL GHR GH1
11 alcohol use disorder 31.6 SLC6A4 POMC NPY CRH BDNF
12 hypogonadism 31.6 PRL POMC LEPR LEP IGF1 GH1
13 obsessive-compulsive disorder 31.6 SLC6A4 PRL POMC NPY LEP HTR2A
14 turner syndrome 31.5 LEP IGF1 GHR GH1
15 anxiety 31.5 SLC6A4 PRL POMC NPY LEP IGF1
16 leptin deficiency or dysfunction 31.5 RETN PYY POMC NPY LEPR LEP
17 gastroparesis 31.4 SLC6A4 GHRL CCK
18 borderline personality disorder 31.4 SLC6A4 PRL HTR2A CRH BDNF
19 obsessive-compulsive personality disorder 31.4 SLC6A4 HTR2A
20 mood disorder 31.4 SLC6A4 POMC NPY HTR2A HCRT CRH
21 hypogonadotropic hypogonadism 31.4 PRL POMC LEPR LEP IGF1
22 celiac disease 1 31.3 PYY LEP IGF1 GHRL CCK
23 type 1 diabetes mellitus 31.3 LEPR LEP IGF1 GHRL GHR GH1
24 hypoglycemia 31.3 PRL POMC NPY LEP IGF1 GHRL
25 osteoporosis 31.3 RETN PRL LEPR LEP IGF1 GHRL
26 protein-energy malnutrition 31.3 LEP IGF1 CCK
27 neurotic disorder 31.3 SLC6A4 POMC HTR2A CRH BDNF
28 major depressive disorder 31.3 SLC6A4 PRL POMC NPY LEP HTR2A
29 conn's syndrome 31.3 RETN PRL POMC LEP IGF1 GHRL
30 adult syndrome 31.3 POMC LEP IGF1 CRH ADIPOQ
31 psychotic disorder 31.3 SLC6A4 PRL NPY HTR2A CRH CCK
32 alcohol dependence 31.2 SLC6A4 POMC NPY LEP HTR2A GHRL
33 social phobia 31.2 SLC6A4 PRL POMC HTR2A CRH CCK
34 pituitary hormone deficiency, combined, 2 31.1 PRL POMC IGF1 GHR GH1
35 substance abuse 31.1 SLC6A4 PRL POMC NPY HTR2A HCRT
36 pituitary-dependent cushing's disease 31.1 PRL POMC GH1 CRH
37 bipolar disorder 31.1 SLC6A4 PRL LEP IGF1 HTR2A CRH
38 endogenous depression 31.1 SLC6A4 PRL POMC HTR2A CRH BDNF
39 hypothyroidism 31.1 RETN PRL POMC LEP IGF1 GHR
40 somatoform disorder 31.0 SLC6A4 POMC HTR2A CRH BDNF
41 generalized anxiety disorder 31.0 SLC6A4 POMC HTR2A CRH BDNF
42 acne 31.0 PRL POMC LEP IGF1 CRH
43 panic disorder 31.0 SLC6A4 PRL POMC NPY HTR2A GHRL
44 hypopituitarism 31.0 PRL POMC LEP IGF1 GHR GH1
45 acute stress disorder 31.0 SLC6A4 POMC HTR2A CRH BDNF
46 schizoaffective disorder 31.0 SLC6A4 PRL HTR2A BDNF
47 premature ovarian failure 7 31.0 POMC GH1 CRH
48 hyperthyroidism 31.0 RETN PRL POMC LEP IGF1 GHRL
49 dysthymic disorder 31.0 SLC6A4 POMC HTR2A HCRT CRH BDNF
50 post-traumatic stress disorder 31.0 SLC6A4 POMC NPY HTR2A HCRT CRH

Comorbidity relations with Anorexia Nervosa via Phenotypic Disease Network (PDN):


Acute Cystitis Major Depressive Disorder
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Anorexia Nervosa:



Diseases related to Anorexia Nervosa

Symptoms & Phenotypes for Anorexia Nervosa

Clinical features from OMIM®:

606788 (Updated 08-Dec-2022)

UMLS symptoms related to Anorexia Nervosa:


decrease in appetite

GenomeRNAi Phenotypes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 AGRP BDNF GHR GHRL IGF1 POMC

MGI Mouse Phenotypes related to Anorexia Nervosa:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.4 ADIPOQ AGRP BDNF CCK CRH GH1
2 homeostasis/metabolism MP:0005376 10.32 ADIPOQ AGRP BDNF CCK CRH GH1
3 adipose tissue MP:0005375 10.22 ADIPOQ AGRP CRH GH1 GHR GHRL
4 renal/urinary system MP:0005367 10.18 ADIPOQ CCK CRH GH1 GHR IGF1
5 liver/biliary system MP:0005370 10.17 ADIPOQ AGRP CRH GH1 GHR LEP
6 growth/size/body region MP:0005378 10.17 ADIPOQ AGRP BDNF CRH GH1 GHR
7 normal MP:0002873 10.16 AGRP BDNF CRH GHRL IGF1 LEPR
8 muscle MP:0005369 10.11 ADIPOQ GHR HCRT HTR2A IGF1 LEP
9 endocrine/exocrine gland MP:0005379 10.1 ADIPOQ BDNF CCK CRH GH1 GHR
10 behavior/neurological MP:0005386 10.06 ADIPOQ AGRP BDNF CRH GH1 GHR
11 respiratory system MP:0005388 9.56 ADIPOQ BDNF CRH GH1 HCRT IGF1
12 integument MP:0010771 9.32 ADIPOQ BDNF CRH GHR IGF1 LEP

Drugs & Therapeutics for Anorexia Nervosa

Drugs for Anorexia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
2
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
3
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5 Antipsychotic Agents Phase 4
6 Dopamine Antagonists Phase 4
7 Dopamine Agents Phase 4
8 Dopamine agonists Phase 4
9 Antiemetics Phase 4
10 Serotonin Uptake Inhibitors Phase 4
11 Gastrointestinal Agents Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Serotonin Receptor Agonists Phase 4
14 Serotonin 5-HT1 Receptor Agonists Phase 4
15
Teriparatide Approved, Investigational Phase 3 52232-67-4 16133850 155817470
16
Levonorgestrel Approved, Investigational Phase 2, Phase 3 797-63-7 13109
17
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3 50-28-2 5757
18
Polyestradiol phosphate Approved Phase 2, Phase 3 28014-46-2
19
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
20
Mecasermin Approved, Investigational Phase 3 68562-41-4
21
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
22
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
23
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0 21873174 65157
24
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
25
Testosterone Approved, Investigational Phase 2, Phase 3 58-22-0 5408 6013
26
Risedronic acid Approved, Investigational Phase 2, Phase 3 105462-24-6 5245
27
Etidronic acid Approved Phase 2, Phase 3 2809-21-4, 7414-83-7 3305
28
Ethinylestradiol Approved Phase 2, Phase 3 57-63-6 5991
29
Racepinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4, 329-65-7 838 5816
30
Alendronic acid Approved Phase 3 121268-17-5, 66376-36-1 2088
31
Ethanol Approved Phase 2, Phase 3 64-17-5 702
32
Naltrexone Approved, Investigational, Vet_approved Phase 2, Phase 3 16590-41-3 5360515
33
Denosumab Approved Phase 3 615258-40-7
34
Prasterone Approved, Investigational, Nutraceutical Phase 2, Phase 3 53-43-0 5881
35
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
36 Appetite Depressants Phase 3
37 Estrogens Phase 2, Phase 3
38 Estradiol 3-benzoate Phase 2, Phase 3
39 Estradiol 17 beta-cypionate Phase 2, Phase 3
40 Hormones Phase 2, Phase 3
41 Hormone Antagonists Phase 2, Phase 3
42 Mitogens Phase 2, Phase 3
43 Analgesics, Non-Narcotic Phase 3
44 Analgesics Phase 3
45 Anabolic Agents Phase 2, Phase 3
46 Androgens Phase 2, Phase 3
47 Testosterone 17 beta-cypionate Phase 2, Phase 3
48 Pharmaceutical Solutions Phase 2, Phase 3
49 calcium channel blockers Phase 2, Phase 3
50 Progestins Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 303)
# Name Status NCT ID Phase Drugs
1 Efficacy of Adapted Program of Physiotherapy in Hospitalized Person by Anorexia Nervosa With Several Undernutrition Completed NCT04190290 Phase 4
2 Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
3 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
4 Fluoxetine After Weight Restoration in Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
5 Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
6 Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
7 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
8 Efficacy of Aripiprazole in the Treatment of Anorexia Nervosa in Teenagers: a Pilot, Randomised, Double Blind, Placebo-controlled Clinical Trial Unknown status NCT01082848 Phase 3 aripiprazole;placebo
9 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
10 Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study Completed NCT03292146 Phase 3 Denosumab 60 MG [Prolia];Placebo Injection;Alendronate 70Mg Tab
11 Cannabinoid CB1 Receptor Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3 dronabinol;placebo
12 IGF-1 and Bone Loss in Women Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3 Testosterone;Actonel (risedronate);Placebo Actonel (risedronate);Placebo testosterone
13 Effects of Anorexia Nervosa on Peak Bone Mass Completed NCT00088153 Phase 2, Phase 3 Physiologic Estrogen/progesterone
14 Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
15 Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
16 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa. Therapeutic Trial of Growth Hormone Completed NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
17 Effects of Anorexia Nervosa on Peak Bone Mass Completed NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
18 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
19 Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study Recruiting NCT04779216 Phase 3 Romosozumab Prefilled Syringe;Placebo;Alendronate 70Mg Tab
20 A Double-Blind Placebo-Controlled Evaluation of Effectiveness of Oral Naltrexone in Management of Adolescent Eating Disorders Enrolling by invitation NCT05073679 Phase 2, Phase 3 Naltrexone Hydrochloride
21 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Terminated NCT02567279 Phase 3 Denosumab subcutaneous injections;Placebo subcutaneous injections
22 Evaluation of the Efficacy and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Children and Adolescents: An Open-label Trial Terminated NCT01184443 Phase 3 Olanzapine
23 A 10-week Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Omega-3 Fatty Acids Oral Capsules Compared With Placebo in the Treatment of Anorexia Nervosa Unknown status NCT01761942 Phase 2
24 Effects of Recombinant Human Insulin Like Growth Factor-1 (rhIGF-1) on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
25 Atypical Antipsychotic Medication in Anorexia Nervosa Completed NCT00692185 Phase 2 Olanzapine;Placebo
26 Treatment of Anxiety and Anorexia Nervosa in Adolescents Completed NCT01933243 Phase 2 Fish oil;Placebo pill
27 Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy Completed NCT04661514 Phase 2 Psilocybin
28 The Role of PTH in Low Bone Mass in Anorexia Nervosa Completed NCT00759772 Phase 2 Placebo;Teriparatide
29 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa Completed NCT02475265 Phase 2 estradiol 0.045 mg/levonorgestrel 0.015mg
30 Treatment for Adolescent Anorexia Nervosa Completed NCT00183586 Phase 2
31 Addressing Fear of Food in Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
32 A Phase 2, Investigator-Initiated, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa Completed NCT01642550 Phase 2 RM-131;Placebo
33 The Effect of Ortho Tri-Cyclen on Bone Mineral Density in Pediatric Subjects With Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study Completed NCT00320567 Phase 2 norgestimate/ethinyl estradiol
34 Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
35 Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa: A Double Blind Placebo Controlled Study Completed NCT00260962 Phase 2 Olanzapine
36 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2 Testosterone;Placebo
37 Therapeutic Effects of Alpha-neurofeedback in the Treatment of Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
38 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
39 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
40 Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa Recruiting NCT03875378 Phase 2 Transdermal estrogen;Placebos
41 Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study Recruiting NCT04505189 Phase 1, Phase 2 Psilocybin
42 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study Recruiting NCT05481736 Phase 2 Psilocybin
43 An Efficacy Study Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage Cancer Enrolling by invitation NCT05170919 Phase 2 Mirtazapine;Olanzapine
44 An Open-Label, Multi-Site Phase 2 Study of the Safety and Feasibility of MDMA-Assisted Psychotherapy for Eating Disorders Not yet recruiting NCT04454684 Phase 2 MDMA
45 A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study Terminated NCT00584688 Phase 2 quetiapine
46 Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Effects of an Estrogen-progestin Combination as add-on to Inpatient Psychotherapy in Adult Female Patients Suffering From Anorexia Nervosa Terminated NCT03172533 Phase 2 ethinyl estradiol 0.03mg and dienogest 2 mg (combination);Placebo oral capsule
47 The Effect of Testosterone Replacement on Bone Mineral Density and Bone Microarchitecture in Teenage Boys and Young Adult Men With Anorexia Nervosa Withdrawn NCT00853502 Phase 2 testosterone cypionate
48 Disseminating Eating Disorders Education and Treatment Across Multiple Levels of Care: Improving Access in the Rhode Island Medicaid Population Unknown status NCT03855553 Phase 1
49 Evaluation of a Computerized Attention Training (CAT) to Modify Attention Bias for Food Cues in Anorexia Nervosa Patients Unknown status NCT02484599 Phase 1
50 Acceptance Based Separated Family Treatment for Adolescents With Anorexia Nervosa Completed NCT01280799 Phase 1

Search NIH Clinical Center for Anorexia Nervosa

Cochrane evidence based reviews: anorexia nervosa

Genetic Tests for Anorexia Nervosa

Genetic tests related to Anorexia Nervosa:

# Genetic test Affiliating Genes
1 Anorexia Nervosa, Susceptibility to, 1 28 HTR2A

Anatomical Context for Anorexia Nervosa

Organs/tissues related to Anorexia Nervosa:

MalaCards : Bone, Prefrontal Cortex, Brain, Cortex, Heart, Bone Marrow, Liver

Publications for Anorexia Nervosa

Articles related to Anorexia Nervosa:

(show top 50) (show all 14850)
# Title Authors PMID Year
1
Haplotype analysis of the COMT-ARVCF gene region in Israeli anorexia nervosa family trios. 53 62 57
16118784 2005
2
Epistatic interaction between the monoamine oxidase A and serotonin transporter genes in anorexia nervosa. 53 62 57
15523490 2005
3
Combined family trio and case-control analysis of the COMT Val158Met polymorphism in European patients with anorexia nervosa. 53 62 57
14681918 2004
4
Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients. 53 62 57
11317231 2001
5
Genetic susceptibility to eating disorders: associated polymorphisms and pharmacogenetic suggestions. 62 57
18855537 2008
6
Linkage analysis of anorexia and bulimia nervosa cohorts using selected behavioral phenotypes as quantitative traits or covariates. 62 57
16152574 2005
7
Evidence for a susceptibility gene for anorexia nervosa on chromosome 1. 62 57
11799475 2002
8
Linkage analysis of anorexia nervosa incorporating behavioral covariates. 62 57
11912184 2002
9
Anorexia nervosa and major depression: shared genetic and environmental risk factors. 62 57
10698830 2000
10
A controlled family study of anorexia nervosa and bulimia nervosa: psychiatric disorders in first-degree relatives and effects of proband comorbidity. 62 57
9672050 1998
11
Mortality in anorexia nervosa. 62 57
7793446 1995
12
Anorexia nervosa: a study of 34 twin pairs and one set of triplets. 62 57
6593110 1984
13
Significant linkage on chromosome 10p in families with bulimia nervosa. 57
12476400 2003
14
Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. 53 62
20339027 2010
15
Peptide YY levels across pubertal stages and associations with growth hormone. 53 62
20375207 2010
16
Correlation of BDNF blood levels with interoceptive awareness and maturity fears in anorexia and bulimia nervosa patients. 53 62
20195875 2010
17
Possible involvement of ghrelin on pain threshold in obesity. 53 62
19883981 2010
18
Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. 53 62
19931436 2010
19
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. 53 62
18574484 2010
20
Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. 53 62
19926712 2010
21
Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects. 53 62
19659925 2009
22
[Neuropeptide Y, ghrelin and leptin plasma levels in anorexia nervosa patients and their changes during six-week refeeding]. 53 62
19947235 2009
23
Adipocyte fatty acid binding protein during refeeding of female patients with anorexia nervosa. 53 62
19421706 2009
24
Functional variants of the serotonin receptor type 3A and B gene are associated with eating disorders. 53 62
19741568 2009
25
Leptin deficiency: clinical implications and opportunities for therapeutic interventions. 53 62
19730134 2009
26
Leptin concentration indexed to fat mass is increased in untreated anorexia nervosa (AN) patients. 53 62
18803679 2009
27
Serum brain-derived neurotrophic factor and peripheral indicators of the serotonin system in underweight and weight-recovered adolescent girls and women with anorexia nervosa. 53 62
19568484 2009
28
Brain-derived neurotrophic factor (BDNF) and set-shifting in currently ill and recovered anorexia nervosa (AN) patients. 53 62
18752728 2009
29
The role of leptin and cortisol in hyperactivity in patients with acute and weight-recovered anorexia nervosa. 53 62
19296912 2009
30
[Relationships of hormones of adipose tissue and ghrelin to bone metabolism]. 53 62
19662887 2009
31
Elevated cannabinoid 1 receptor mRNA is linked to eating disorder related behavior and attitudes in females with eating disorders. 53 62
19046818 2009
32
Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. 53 62
18995969 2009
33
Leptin, ghrelin, and endocannabinoids: potential therapeutic targets in anorexia nervosa. 53 62
18926548 2009
34
NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. 53 62
20066808 2009
35
Leptin in humans: lessons from translational research. 53 62
19176740 2009
36
Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hormones to food in eating disorders. 53 62
19176730 2009
37
Mecasermin (recombinant human insulin-like growth factor I). 53 62
19198769 2009
38
Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. 53 62
19755753 2009
39
Serum concentrations of adipocyte fatty acid binding protein in patients with anorexia nervosa. 53 62
18657008 2009
40
Leptin and its associations with measures of psychopathology in patients with anorexia nervosa. 53 62
19018447 2009
41
The role of ghrelin in the regulation of food intake in patients with obesity and anorexia nervosa. 53 62
18380540 2009
42
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa. 53 62
19093738 2009
43
Hypercaloric diets differing in fat composition have similar effects on serum leptin and weight gain in female subjects with anorexia nervosa. 53 62
19185771 2009
44
Organic background of restrictive-type anorexia nervosa suggested by increased serotonin 1A receptor binding in right frontotemporal cortex of both lean and recovered patients: [18F]MPPF PET scan study. 53 62
18639866 2008
45
Deranged secretion of ghrelin and obestatin in the cephalic phase of vagal stimulation in women with anorexia nervosa. 53 62
18474361 2008
46
Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. 53 62
19014633 2008
47
The endocrinopathies of anorexia nervosa. 53 62
19095609 2008
48
Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. 53 62
18728162 2008
49
Surged leptin/ghrelin secretion associated with anorexia nervosa. 53 62
18955869 2008
50
Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. 53 62
17919459 2008

Variations for Anorexia Nervosa

Expression for Anorexia Nervosa

Search GEO for disease gene expression data for Anorexia Nervosa.

Pathways for Anorexia Nervosa

Pathways related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 PYY POMC NPY HTR2A HCRT GHRL
2 13.15 PYY POMC NPY LEPR LEP IGF1
3
Show member pathways
13.13 CCK CRH GHRL HCRT HTR2A NPY
4
Show member pathways
12.77 PRL IGF1 GHR GH1 BDNF
5
Show member pathways
11.93 RETN POMC NPY AGRP
6
Show member pathways
11.89 POMC LEP IGF1 GHRL GH1
7 11.71 LEP IGF1 ADIPOQ
8 11.67 RETN LEP IGF1 GH1 ADIPOQ
9 11.64 POMC NPY AGRP
10 11.46 POMC GHRL BDNF
11 11.33 PRL LEPR LEP
12 11.32 LEPR LEP ADIPOQ
13
Show member pathways
11.2 PRL GHR GH1
14
Show member pathways
11.02 POMC LEPR LEP
15
Show member pathways
10.96 POMC HTR2A CRH
16 10.53 PYY PRL POMC NPY LEPR LEP
17 10.37 CRH POMC

GO Terms for Anorexia Nervosa

Cellular components related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.13 ADIPOQ AGRP BDNF CCK CRH GH1
2 extracellular region GO:0005576 9.84 ADIPOQ AGRP BDNF CCK CRH GH1
3 growth hormone receptor complex GO:0070195 9.46 GHR GH1

Biological processes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.44 RETN PRL POMC LEP IGF1 HTR2A
2 glucose homeostasis GO:0042593 10.2 POMC LEPR LEP ADIPOQ
3 neuropeptide signaling pathway GO:0007218 10.13 AGRP HCRT NPY POMC PYY
4 hormone-mediated signaling pathway GO:0009755 10.1 GHRL GHR AGRP
5 circadian rhythm GO:0007623 10.1 ADIPOQ AGRP LEP SLC6A4
6 positive regulation of cold-induced thermogenesis GO:0120162 10.1 LEPR LEP HCRT GHRL ADIPOQ
7 negative regulation of tumor necrosis factor production GO:0032720 10.08 POMC IGF1 GHRL ADIPOQ
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.06 LEP IGF1 GHR GH1
9 positive regulation of multicellular organism growth GO:0040018 10.02 GHRL GHR GH1
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.02 IGF1 HTR2A GHR GH1 ADIPOQ
11 regulation of multicellular organism growth GO:0040014 10.01 PRL IGF1 GHR
12 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.97 GH1 GHR LEP PRL
13 negative regulation of potassium ion transport GO:0043267 9.93 HTR2A HCRT
14 bone mineralization involved in bone maturation GO:0035630 9.92 LEP IGF1
15 regulation of bone remodeling GO:0046850 9.91 LEPR LEP
16 bone growth GO:0098868 9.91 LEP LEPR
17 positive regulation of appetite GO:0032100 9.89 GHRL NPY
18 positive regulation of corticotropin secretion GO:0051461 9.88 CRH GHRL
19 positive regulation of cortisol secretion GO:0051464 9.88 CRH GHRL
20 negative regulation of glucagon secretion GO:0070093 9.87 CRH LEP
21 positive regulation of eating behavior GO:1904000 9.86 GHRL NPY
22 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.83 CRH GHRL
23 positive regulation of feeding behavior GO:2000253 9.8 GHRL AGRP
24 feeding behavior GO:0007631 9.8 PYY NPY HCRT AGRP
25 eating behavior GO:0042755 9.76 AGRP CCK HCRT LEP
26 response to nutrient levels GO:0031667 9.5 PRL LEP GHRL GH1 ADIPOQ
27 adult feeding behavior GO:0008343 9.23 NPY LEP GHRL AGRP

Molecular functions related to Anorexia Nervosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.93 ADIPOQ AGRP BDNF CRH LEP NPY
2 G protein-coupled receptor binding GO:0001664 9.86 PYY POMC NPY GHRL
3 peptide hormone receptor binding GO:0051428 9.73 LEP CCK
4 neuropeptide hormone activity GO:0005184 9.73 PYY NPY HCRT CRH CCK AGRP
5 type 1 melanocortin receptor binding GO:0070996 9.71 POMC AGRP
6 hormone activity GO:0005179 9.68 ADIPOQ CCK CRH GH1 GHRL IGF1
7 neuropeptide Y receptor binding GO:0031841 9.67 PYY NPY
8 prolactin receptor binding GO:0005148 9.62 PRL GH1

Sources for Anorexia Nervosa

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....